Meeting
2020 ASCO Virtual Scientific Program
Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).
Authors
William Kevin Kelly
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA
William Kevin Kelly , Benjamin Leiby , David Johnson Einstein , Russell Zelig Szmulewitz , A. Oliver Sartor , Eddy Shih-Hsin Yang , Guru Sonpavde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03076203
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5540)
DOI
10.1200/JCO.2020.38.15_suppl.5540
Abstract #
5540
Poster Bd #
121
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).
First Author: Eddy Shih-Hsin Yang
Poster
2019 ASCO Annual Meeting
High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).
First Author: Julia Chen
Poster
2024 ASCO Genitourinary Cancers Symposium
Days spent with healthcare contact by patients with metastatic castrate-resistant prostate cancer in the last year of life.
First Author: Daniel Sentana Lledo
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier